Beyond Sensitivity: Lessons From Developing A Robust Multi-Matrix qPCR Assay For AAV Vector Shedding

If you're developing or validating AAV gene therapy shedding assays, the matrix problem is probably already on your radar. Whole blood, semen, urine, saliva, and serum aren't interchangeable, and treating them as though they are is a fast route to unreliable qPCR data. Each matrix brings its own cellular composition, endogenous nucleic acid background, and inhibitor load, and a single extraction protocol rarely survives contact with all of them.

Work by Vikas Singh and colleagues at Eurofins Viracor BioPharma Services makes this concrete. Their validation study across multiple sample types illustrates why matrix-specific optimization isn't a nice-to-have, it's a prerequisite for the kind of reproducible, sensitive data that regulatory agencies expect from comprehensive shedding programs.

The stakes are real. Regulators require shedding assessments to evaluate transmission risks to caregivers, family members, and healthcare workers across respiratory, gastrointestinal, sexual, and potential vertical routes. Getting extraction right upstream protects the integrity of everything downstream.

Access the full analysis to sharpen your extraction strategy and build shedding assays that hold up under regulatory scrutiny.